-
Clinical Trials & Development2 weeks agoXBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial of Vilamakitug in Refractory Metastatic Colorectal Cancer
AUSTIN, Texas, Oct. 19, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced positive final efficacy results from the randomized Phase II portion of the...
-
Clinical Trials & Development2 weeks ago
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of Duravyu™ in Wet AMD
WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
-
Clinical Trials & Development2 weeks agoCould a metabolic lens on mortality reshape clinical trials?
BIOCENTURY | DISCOVERY & TRANSLATIONCOULD A METABOLIC LENS ON MORTALITY RESHAPE CLINICAL TRIALS?The metabolic vulnerability index captures overlooked mortality risk, with stronger predictions of death than...
-
Clinical Trials & Development2 weeks agoSafety Reporting Requirements for INDs and BA/BE Studies
Guidance for Industry and Investigators - Safety Reporting Requirements for INDs and BA/BE Studies, Drug Safety
-
Clinical Trials & Development2 weeks agoAs AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder...
-
Clinical Trials & Development2 weeks agoNovartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues
Novartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read out...
-
Clinical Trials & Development2 weeks agoVeradermics’ minoxidil pill improves hair coverage in men in Phase 3
In the wake of a successful IPO and strong stock growth throughout the year, Veradermics now has late-stage data to support a regulatory package for its...
-
Clinical Trials & Development2 weeks agoSTAT+: Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
An oral treatment from Gilead Sciences eliminated the symptoms experienced by patients with a type of inflammatory bowel disease, according to mid-stage study results reported Monday.
-
Clinical Trials & Development2 weeks agoLandmark Trial Tests Whether Chemotherapy Can Be Spared in High-Risk Early Breast Cancer
The new phase 3 RxFINE-Low trial will test whether patients with low genomic risk but high anatomic risk early-stage breast cancer can safely omit chemotherapy when...
-
Clinical Trials & Development2 weeks ago
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
